Artiva Biotherapeutics ARTV
- Market cap
- $204.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −37.5%
Artiva Biotherapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $26.7M | $2.4M | n/a | n/a | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $13.1M | $11.2M | $11.2M−25% | $12.3M+10% | $13.5M+4% | $13.3M+19% | $17.1M+53% | $17.9M+45% | $17.6M+30% | $17M+28% | $19.3M+13% | $21.9M+23% |
| SG&A | $2.8M | $3.2M | $3.6M−8% | $3.9M−5% | $4.8M+73% | $5M+56% | $5.1M+43% | $4.9M+28% | $5.3M+9% | $4.9M−0% | $5.1M+0% | $5M+0% |
| $10.8M | −$12M | −$14.5M−18% | −$16.2M+37% | −$18.3M | −$18.3M+53% | −$22.2M+53% | −$22.8M+41% | −$22.9M+25% | −$21.9M+20% | −$24.4M+10% | −$26.9M+18% | |
| Net income | $11.3M | −$12M | −$14M−17% | −$17.8M+58% | −$17.5M | −$16.1M+34% | −$20.3M+46% | −$21.3M+19% | −$21.5M+23% | −$20.8M+29% | −$23.5M+16% | −$25M+18% |
| $1.62 | −$14.83 | −$17.24−18% | −$22.00+56% | −$0.92 | −$0.66−96% | −$0.83−95% | −$0.87−96% | −$0.88−4% | −$0.85+29% | −$0.95+15% | −$0.63−28% | |
| 7M | 809.3K | 809.8K+2% | 811.2K+1% | 18.9M+171% | 24.3M+2901% | 24.3M+2906% | 24.4M+2905% | 24.5M+30% | 24.6M+1% | 24.7M+1% | 39.4M+62% |
Revenue: Q1 FY23: 6 months less the 3 months printed beside them.
R&D: Q1 FY23: 6 months less the 3 months printed beside them.
SG&A: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Operating income: Q1 FY23: 6 months less the 3 months printed beside them.
Net income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY23 and Q1 FY24: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Artiva Biotherapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ARTVArtiva Biotherapeutics | $204.8M | n/m | n/a | n/m | n/m | n/m | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $223.9M | 20.4× | 29.0× | 3.0× | +15% | 15.3% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| CYHCommunity Health Systems | $296.2M | 8.1× | 4.5× | 0.0× | −8% | 0.3% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| VMDViemed Healthcare | $359.6M | 26.2× | 26.2× | 1.2× | +25% | 4.8% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| Peer median | $250.1M | 13.9× | 20.5× | 1.6× | +10% | 11.9% |
Investors who own it
Investors we follow who held Artiva Biotherapeutics at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors0.1% of portfolionew
More on Artiva Biotherapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .